|
| Author (year) | Trial design/phase | G-CSF regimen | Time after stroke | Patients (intervention/control) | Comments |
|
| Floel et al. (2011) | Randomized controlled trial | 10 μg/kg s/c for 10 days | 4 months after | 21 Intervention 20 Placebo | Feasibility and safe and reasonable tolerable in chronic stroke patients |
| Schäbitz et al. (2010) | Randomized, placebo-controlled | 30 μg/kg,
90 μg/kg,
135 μg/kg,
180 μg/kg | Within 12 hours | 14/ Placebo
8/30 μg/kg
7/90 μg/kg
8/135 μg/kg
7/180 μg/kg | Well tolerated even in higher doses and Treatment effect in patients with higher volume of lesion size (˃14–17 cm3) at baseline |
| Shyu et al. (2006) | Single blind controlled/pilot | 15 μg/kg/day s/c for 5 days | Within 7 days | 7 Intervention
15 μg/kg/day s/c
for 5 days 3 Control | No thrombotic complications, and improved outcome in G-CSF group
NIHSS 59% in G-CSF group, 36% in controls group BI 120% in G-CSF group, and 60% in controls group |
| Sprigg et al. (2006) | Double-blind placebo-controlled/pilot | Dose escalation 1–10 μg/kg s/c for 1 or 5 days | 7–30 days | 12/Placebo
4/1 μg/kg (single dose)
4/3 μg/kg (single dose)
4/10 μg/kg (single dose)
4/1 μg/kg (five dose)
4/3 μg/kg (five dose)
4/10 μg/kg (five dose) | No difference in SAEs although non significant increase in infection rates in active group
Significant increase in CD-34+ with 10 μg/kg (five dose) at day five |
| Zhang (2006) | Double-blind placebo-controlled/pilot | 2 μg/kg/day s/c for 5 days | Within 7 days | 15 Intervention 30 Control | No difference in adverse events reported and significant reduction in NIHSS |
|
